Colchicine for cardiovascular therapy: A drug interaction perspective and a safety meta-analysis

Código QR

Colchicine for cardiovascular therapy: A drug interaction perspective and a safety meta-analysis

Guardado en:

Detalles Bibliográficos
Autores principales:	Selçuk Şen, Eda Karahan, Cansu Büyükulaş, Yasin Onur Polat, Ali Yağız Üresin
Formato:	article
Lenguaje:	EN
Publicado:	KARE Publishing 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/d15a7cfba97b4ee9997ef0f54b8ba516
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Impact of colchicine on mortality in patients with COVID-19: A meta-analysis
por: Dimitrios A. Vrachatis, et al.
Publicado: (2021)

Association Between Colchicine Treatment and Clinical Outcomes in Patients with Coronary Artery Disease: Systematic Review and Meta-analysis
por: Francesco Condello, et al.
Publicado: (2021)

Colchicine, fragmented QRS, coronavirus disease 2019, and more
por: Çetin Erol
Publicado: (2021)

Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis
por: BMY Cheung, et al.
Publicado: (2020)

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
por: Alberto J Lorenzatti, et al.
Publicado: (2020)

Safety and Effectiveness of Coronary Angiography or Intervention through the Distal Radial Access: A Meta-Analysis
por: Jun Cao, et al.
Publicado: (2021)

Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
por: Chris Wai Hang Lo, et al.
Publicado: (2021)

Perioperative myocardial damage and the incidence of type 2 myocardial infarction in patients with intermediate and high cardiovascular risk
por: Miraç Vural Keskinler, et al.
Publicado: (2021)

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
por: Mustafa Kılıçkap, et al.
Publicado: (2021)

Does coexistence of fragmented QRS and cardiovascular disease have the ability to predict the mortality in hospitalized, critically ill patients with COVID-19?
por: Fahrettin Katkat, et al.
Publicado: (2021)

Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
por: Mattia Cattaneo, et al.
Publicado: (2019)

The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis
por: Xiangwen Liang, et al.
Publicado: (2021)

Cardiovascular Pharmacotherapy Focus
por: Pablo Avanzas
Publicado: (2019)

Inflammation and Cardiovascular Disease: The Future
por: Natalie Arnold, et al.
Publicado: (2021)

The Effect of Testosterone on Cardiovascular Disease and Cardiovascular Risk Factors in Men: A Review of Clinical and Preclinical Data
por: Hargun Kaur, et al.
Publicado: (2021)

Flight safety in patients with arrhythmia
por: Fahrettin Katkat
Publicado: (2021)

Meditation and Cardiovascular Health: What is the Link?
por: Sebastian Schnaubelt, et al.
Publicado: (2019)

COVID-19 Pandemic and Cardiovascular Disease
por: Aniket S Rali, et al.
Publicado: (2020)

Deciphering the Riddles in Nutrition and Cardiovascular Disease
por: Amelia Carro, et al.
Publicado: (2019)

The Association Between Psoriasis and Cardiovascular Diseases
por: Ahmed Zwain, et al.
Publicado: (2021)

Effects of aerospace environments on the cardiovascular system
por: Erdinç Ercan
Publicado: (2021)

Very Long-term Safety and Effectiveness of Drug-Eluting or Bare-Metal Stents for Left Main Coronary Disease
por: Hanbit Park, MD, et al.
Publicado: (2021)

Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review
por: Esmee ME Bovee, et al.
Publicado: (2021)

Coronavirus disease 2019 and flight safety
por: Sevgi Özcan
Publicado: (2021)

Unsolved issues of The Efficacy and Safety of Edoxaban
por: Leszek Drabik, et al.
Publicado: (2021)

Viscoelastic Haemostatic Assays in Cardiovascular Critical Care
por: Aniket S Rali, et al.
Publicado: (2021)

Electronic Cigarettes and Cardiovascular Risk: Caution Waiting for Evidence
por: Domenico D’Amario, et al.
Publicado: (2019)

Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
por: Aarti Thakkar, et al.
Publicado: (2021)

Coronavirus Disease 2019: Psychological Stress and Cardiovascular Diseases
por: Maki Komiyama, et al.
Publicado: (2021)

The Fourth Trimester: Pregnancy as a Predictor of Cardiovascular Disease
por: Pensée Wu, et al.
Publicado: (2021)

New opportunities for reducing cardiovascular risk in the Russian Federation
por: O. D. Ostroumova, et al.
Publicado: (2020)

Obesity and Cardiovascular Risk After Quitting Smoking: The Latest Evidence
por: Koji Hasegawa, et al.
Publicado: (2019)

Electronic Cigarettes and Cardiovascular Risk: Science, Policy and the Cost of Certainty
por: Olusola A Orimoloye, et al.
Publicado: (2019)

Non-invasive Low-level Tragus Stimulation in Cardiovascular Diseases
por: Yunqiu Jiang, et al.
Publicado: (2020)

Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials
por: Alberto J Lorenzatti
Publicado: (2021)

Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19
por: Rhian M. Touyz, MBBCh, PhD, et al.
Publicado: (2021)

COVID-19: a patient with cardiovascular disease at high risk
por: Irina E. Chazova, et al.
Publicado: (2020)

Trending cardiac biomarkers during pregnancy in women with cardiovascular disease
por: Soohyun Chang, et al.
Publicado: (2021)

A meta-analysis of randomized controlled trials investigating tirofiban combined with conventional drugs by intracoronary administration for no-reflow prevention
por: Qian Zeng, et al.
Publicado: (2021)

Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use
por: Zoltán Papp, et al.
Publicado: (2020)